Stocks › BMY
Bristol-Myers Squibb Company (BMY) stock analysis
SKIP 2% confidence · analysed Oct 1, 2026
On Oct 1, 2026, our model rated Bristol-Myers Squibb Company (BMY) SKIP with 2% confidence at a price of $61.78. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 38. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is only 0.4x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $61.55 and the swing low is $52.84; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 17.50, which looks expensive relative to its growth.
The company reports a profit margin of 18.9% and revenue growth of +5.7%.
In its latest quarter it earned $2.04 per share, which beat the $1.60 analysts expected, with revenue +5.7% year over year.
Wall Street's average rating is 2.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $66.71.
The next earnings report is expected around Oct 29, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.02 (SKIP). Technicals: RSI 38.25, MACD bearish, price below SMA50. Fundamentals: PEG 17.50, margin 18.9%, revenue growth 5.7%. Financial results: YoY revenue +5.7%, last EPS surprise +27.5%, next earnings 2026-10-29. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Memory: 1 prior look(s). Reference price $61.55; no trade levels (SKIP).
Past ratings for BMY
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 1, 2026 | SKIP | 2% | $61.78 | — |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
BSX · CNC · COO · CVS · DVA · EVH · FTRE · HALO · HUM · IART · ICLR · IRWD
Frequently asked questions
Is BMY a buy right now?
As of Oct 1, 2026, our automated model rates Bristol-Myers Squibb Company (BMY) SKIP with 2% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Bristol-Myers Squibb Company report earnings next?
The next earnings report is expected around Oct 29, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.